|
JPS5566586A
(en)
*
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164687A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55102583A
(en)
*
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55164685A
(en)
*
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164686A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
HU230586B1
(hu)
|
1999-06-25 |
2017-02-28 |
Genentech, Inc. |
Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására
|
|
EP2289549A3
(en)
|
1999-10-01 |
2011-06-15 |
Immunogen, Inc. |
Immunoconjugates for treating cancer
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
CA2447139C
(en)
|
2001-05-11 |
2013-11-19 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
EP2000545B1
(en)
|
2001-06-20 |
2011-08-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of lung tumor
|
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
|
ES2431929T3
(es)
|
2001-09-18 |
2013-11-28 |
Genentech, Inc. |
Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
|
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
US20030228305A1
(en)
|
2002-01-02 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
EP2011886A3
(en)
|
2002-04-16 |
2009-02-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
|
WO2004101756A2
(en)
|
2003-05-09 |
2004-11-25 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
EP3524611B1
(en)
|
2003-05-20 |
2020-12-30 |
ImmunoGen, Inc. |
Improved cytotoxic agents comprising new maytansinoids
|
|
WO2005010151A2
(en)
|
2003-06-27 |
2005-02-03 |
Abgenix, Inc |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
ES2424353T3
(es)
|
2003-07-08 |
2013-10-01 |
Genentech, Inc. |
Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos
|
|
KR20060069825A
(ko)
*
|
2003-08-01 |
2006-06-22 |
제넨테크, 인크. |
제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
|
|
PL2161283T3
(pl)
|
2003-11-17 |
2014-11-28 |
Genentech Inc |
Kompozycja zawierająca przeciwciała przeciwko CD79b skoniugowane ze środkiem hamującym wzrost lub środkiem cytotoksycznym i sposoby leczenia guzów o pochodzeniu hematopoetycznym
|
|
ATE554107T1
(de)
|
2003-12-19 |
2012-05-15 |
Genentech Inc |
Als therapeutika geeignete monovalente antikörperfragmente
|
|
WO2006074418A2
(en)
|
2005-01-07 |
2006-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
CN114053429A
(zh)
*
|
2004-06-01 |
2022-02-18 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
|
DK1771474T3
(da)
|
2004-07-20 |
2010-05-31 |
Genentech Inc |
Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
|
|
EP1774022B1
(en)
|
2004-07-26 |
2014-12-31 |
Genentech, Inc. |
Methods and compositions for modulating hepatocyte growth factor activation
|
|
US20060045877A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Goldmakher Viktor S |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
|
SI2990422T1
(sl)
|
2004-09-03 |
2018-10-30 |
Genentech, Inc. |
Humanizirani antagonisti proti beta7 in njihove uporabe
|
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
WO2007094842A2
(en)
*
|
2005-12-02 |
2007-08-23 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
US7931902B2
(en)
|
2005-08-15 |
2011-04-26 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
|
US20090293137A1
(en)
|
2005-11-21 |
2009-11-26 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
|
US20070237764A1
(en)
*
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
CA2631961A1
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22
|
|
EP2325208B1
(en)
|
2005-12-15 |
2017-09-20 |
Genentech, Inc. |
Polyubiquitin antibodies
|
|
RU2450020C2
(ru)
|
2006-01-05 |
2012-05-10 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
AU2007243132B2
(en)
|
2006-01-20 |
2012-09-13 |
Genentech, Inc. |
Anti-EphrinB2 antibodies and methods using same
|
|
ZA200807714B
(en)
|
2006-02-17 |
2010-01-27 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
CA2647277A1
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
|
WO2008036437A2
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
PT2032606E
(pt)
|
2006-05-30 |
2014-02-05 |
Genentech Inc |
Anticorpos e imunoconjugados e respetivas utilizações
|
|
EP2845912A1
(en)
|
2006-09-12 |
2015-03-11 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker
|
|
EP2845866B1
(en)
|
2006-10-27 |
2017-05-03 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
US8444971B2
(en)
|
2006-11-27 |
2013-05-21 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
|
CN101711284A
(zh)
|
2007-01-25 |
2010-05-19 |
达娜-法勃肿瘤研究所 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
|
CA2676766A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
|
JP5618549B2
(ja)
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
PE20140625A1
(es)
|
2007-07-16 |
2014-05-29 |
Genentech Inc |
ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
|
|
PL2176296T3
(pl)
|
2007-07-16 |
2012-07-31 |
Genentech Inc |
Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
|
|
CA2696360C
(en)
|
2007-08-14 |
2018-11-20 |
Ludwig Institute For Cancer Research |
Monoclonal antibody targeting the egfr receptor and uses thereof
|
|
MX2010005244A
(es)
*
|
2007-11-12 |
2010-10-25 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y el diagnóstico de influenza.
|
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
|
BRPI0821417A2
(pt)
*
|
2007-12-26 |
2015-06-16 |
Biotest Ag |
Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
|
|
AR069979A1
(es)
*
|
2007-12-26 |
2010-03-03 |
Biotest Ag |
Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
|
|
DK2238168T3
(da)
|
2007-12-26 |
2014-08-25 |
Biotest Ag |
Midler, der er målrettet mod cd138 og anvendelser deraf
|
|
RU2547939C2
(ru)
*
|
2007-12-26 |
2015-04-10 |
Биотест Аг |
Иммуноконъюгаты, направленные на cd138, и их применение
|
|
CN101977934B
(zh)
|
2008-01-18 |
2014-09-17 |
健泰科生物技术公司 |
用于靶向k63连接的多聚遍在蛋白的方法和组合物
|
|
PT2247620T
(pt)
|
2008-01-31 |
2016-08-23 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
|
CA2718878A1
(en)
*
|
2008-03-10 |
2009-09-17 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
|
CA2990929C
(en)
|
2008-03-18 |
2022-04-12 |
Genentech, Inc. |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
DK2279412T3
(en)
|
2008-04-09 |
2017-10-16 |
Genentech Inc |
PRESENT UNKNOWN COMPOSITIONS AND PROCEDURES FOR TREATING IMMUNRATED DISEASES
|
|
CN101796640A
(zh)
*
|
2008-05-08 |
2010-08-04 |
松下电器产业株式会社 |
非易失性存储元件、非易失性存储装置、以及其制造方法
|
|
SI2279004T1
(sl)
*
|
2008-05-16 |
2015-05-29 |
F. Hoffmann-La Roche Ag |
Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrina
|
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
|
JP5710487B2
(ja)
|
2008-10-01 |
2015-04-30 |
ジェネンテック， インコーポレイテッド |
抗ｎｏｔｃｈ２抗体および使用方法
|
|
US20120027722A1
(en)
|
2008-12-17 |
2012-02-02 |
Medical Research Council |
Hepatitis c virus combination therapy
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
MA33198B1
(fr)
|
2009-03-20 |
2012-04-02 |
Genentech Inc |
Anticorps anti-her di-spécifiques
|
|
US8410250B2
(en)
|
2009-03-25 |
2013-04-02 |
Genentech, Inc. |
Anti-FGFR3 antibodies and methods using same
|
|
CN102471380B
(zh)
|
2009-04-01 |
2015-01-14 |
霍夫曼-拉罗奇有限公司 |
抗FcRH5抗体和免疫偶联物及使用方法
|
|
AU2010230563A1
(en)
|
2009-04-02 |
2011-09-22 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain Fab fragments
|
|
US8609101B2
(en)
*
|
2009-04-23 |
2013-12-17 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
|
|
AU2010249787A1
(en)
|
2009-05-20 |
2011-12-22 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
|
CN102498129B
(zh)
|
2009-07-31 |
2016-03-02 |
霍夫曼-拉罗奇有限公司 |
使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
|
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
EP2491058A1
(en)
*
|
2009-10-19 |
2012-08-29 |
F. Hoffmann-La Roche AG |
Modulators of hepatocyte growth factor activator
|
|
AU2010310585A1
(en)
|
2009-10-22 |
2012-05-03 |
Genentech, Inc. |
Anti-hepsin antibodies and methods using same
|
|
EP2490718B1
(en)
|
2009-10-22 |
2016-01-13 |
F.Hoffmann-La Roche Ag |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
|
WO2011057120A1
(en)
|
2009-11-05 |
2011-05-12 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
|
SG10201408598XA
(en)
|
2009-11-30 |
2015-02-27 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
ES2565208T3
(es)
|
2009-12-11 |
2016-04-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-VEGF-C y métodos de uso de los mismos
|
|
DK2516465T3
(en)
|
2009-12-23 |
2016-06-06 |
Hoffmann La Roche |
ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
|
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
|
PH12012501680A1
(en)
|
2010-02-23 |
2012-11-05 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
ES2617777T5
(es)
|
2010-04-23 |
2022-10-13 |
Hoffmann La Roche |
Producción de proteínas heteromultiméricas
|
|
CN102958941A
(zh)
|
2010-05-03 |
2013-03-06 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
|
SG185430A1
(en)
|
2010-06-03 |
2012-12-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
|
EP2603237A4
(en)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
|
|
JP5758004B2
(ja)
|
2010-08-24 |
2015-08-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
|
|
EP3556396B1
(en)
|
2010-08-31 |
2022-04-20 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
|
NZ607510A
(en)
|
2010-09-10 |
2014-10-31 |
Apexigen Inc |
Anti-il-1 beta antibodies and methods of use
|
|
CA2813738A1
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
CN103649117B
(zh)
|
2011-02-04 |
2016-09-14 |
霍夫曼-拉罗奇有限公司 |
Fc变体及其生成方法
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
JP2014506580A
(ja)
|
2011-02-14 |
2014-03-17 |
セラクローン サイエンシーズ， インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
|
RU2013144392A
(ru)
|
2011-03-03 |
2015-04-10 |
Апексиджен, Инк. |
Антитела к рецептору il-6 и способы применения
|
|
CA2829968A1
(en)
|
2011-03-15 |
2012-09-20 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
AU2012249454B2
(en)
|
2011-04-29 |
2016-03-24 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
CA2835203A1
(en)
|
2011-05-09 |
2012-11-15 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
|
EP3693394A1
(en)
|
2011-05-27 |
2020-08-12 |
Glaxo Group Limited |
Antigen binding proteins
|
|
BR112014003599A2
(pt)
|
2011-08-17 |
2018-04-17 |
Genentech Inc |
método de inibição da angiogênese tumoral, método de supressão do crescimento tumoral e método de tratamento de tumor
|
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
|
PE20141151A1
(es)
|
2011-09-22 |
2014-09-25 |
Amgen Inc |
Proteinas de union al antigeno cd27l
|
|
EA201490879A1
(ru)
|
2011-10-28 |
2014-08-29 |
Дженентек, Инк. |
Терапевтические комбинации и способы лечения меланомы
|
|
WO2013067098A1
(en)
|
2011-11-02 |
2013-05-10 |
Apexigen, Inc. |
Anti-kdr antibodies and methods of use
|
|
HK1202252A1
(en)
|
2011-11-16 |
2015-09-25 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
|
US10117932B2
(en)
|
2011-12-08 |
2018-11-06 |
Biotest Ag |
Uses of immunoconjugates targeting CD138
|
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
|
CA2862979A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック， インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
|
HK1203972A1
(en)
|
2012-03-08 |
2015-11-06 |
Halozyme, Inc. |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
AR090903A1
(es)
|
2012-05-01 |
2014-12-17 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-pmel17
|
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
|
CN110256567B
(zh)
|
2012-06-27 |
2023-04-25 |
弗·哈夫曼-拉罗切有限公司 |
用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途
|
|
JP6309002B2
(ja)
|
2012-06-27 |
2018-04-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
|
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
SI3486248T1
(sl)
|
2012-09-26 |
2021-10-29 |
Immunogen Inc |
Izboljšane metode za aciliranje majtanzinola
|
|
JP6693745B2
(ja)
|
2012-10-30 |
2020-05-13 |
アペクシジェン， インコーポレイテッド |
抗ｃｄ４０抗体および使用方法
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
|
US9789203B2
(en)
|
2013-03-15 |
2017-10-17 |
Novartis Ag |
cKIT antibody drug conjugates
|
|
PT3004167T
(pt)
|
2013-05-30 |
2018-11-13 |
Kiniksa Pharmaceuticals Ltd |
Proteínas de ligação ao antigénio do recetor da oncostatina m
|
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
EP3013347B1
(en)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
|
EP3027208B1
(en)
|
2013-07-31 |
2020-06-24 |
Biontech AG |
Diagnosis and therapy of cancer involving cancer stem cells
|
|
AU2014317889B2
(en)
|
2013-09-06 |
2020-03-05 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
|
KR20160055253A
(ko)
|
2013-09-12 |
2016-05-17 |
할로자임, 아이엔씨 |
변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
|
|
CA2922889A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
|
WO2015054691A2
(en)
|
2013-10-11 |
2015-04-16 |
The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services |
Tem8 antibodies and their use
|
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
AU2014362238A1
(en)
|
2013-12-13 |
2016-06-09 |
Genentech, Inc. |
Anti-CD33 antibodies and immunoconjugates
|
|
UA118113C2
(uk)
|
2013-12-16 |
2018-11-26 |
Дженентек, Інк. |
Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
|
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
MX2016009515A
(es)
|
2014-01-24 |
2016-10-26 |
Genentech Inc |
Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados.
|
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
EP3129767B1
(en)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
|
KR20160143808A
(ko)
|
2014-04-11 |
2016-12-14 |
메디뮨 엘엘씨 |
이중특이적 her2 항체
|
|
HUE063273T2
(hu)
|
2014-05-06 |
2024-01-28 |
Hoffmann La Roche |
Heteromultimer fehérjék elõállítása emlõssejtek felhasználásával
|
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
KR20170010003A
(ko)
|
2014-05-27 |
2017-01-25 |
아카데미아 시니카 |
박테로이드 기원의 푸코시다제 및 이의 사용 방법
|
|
TWI679020B
(zh)
|
2014-05-27 |
2019-12-11 |
中央研究院 |
抗ｈｅｒ２醣抗體及其用途
|
|
US20150344585A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
|
KR102494193B1
(ko)
|
2014-05-28 |
2023-01-31 |
아카데미아 시니카 |
항-ｔｎｆ-알파 글리코항체 및 이의 용도
|
|
AP2017009719A0
(en)
|
2014-08-12 |
2017-01-31 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
|
DK3186284T3
(da)
|
2014-08-28 |
2022-05-09 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
EP3191500A4
(en)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
|
EP3191518B1
(en)
|
2014-09-12 |
2020-01-15 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
ES2830385T3
(es)
|
2014-09-12 |
2021-06-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-HER2
|
|
AU2015314744A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
EP3200829B1
(en)
|
2014-10-01 |
2023-12-06 |
Medimmune, LLC |
Method of conjugating a polypeptide
|
|
KR20170080675A
(ko)
|
2014-11-05 |
2017-07-10 |
제넨테크, 인크. |
항-fgfr2/3 항체 및 이의 이용 방법
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
|
JP2018510844A
(ja)
|
2015-01-24 |
2018-04-19 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
がんマーカーおよびその使用方法
|
|
AU2016215227A1
(en)
|
2015-02-04 |
2017-09-21 |
Assistance Publique-Hopitaux De Paris |
Mutant smoothened and methods of using the same
|
|
CA2979895A1
(en)
|
2015-03-18 |
2016-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
|
WO2016165762A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Drug conjugates comprising antibodies against claudin 18.2
|
|
KR102668727B1
(ko)
|
2015-04-24 |
2024-05-28 |
제넨테크, 인크. |
다중특이적 항원-결합 단백질
|
|
EP4286511A3
(en)
|
2015-06-12 |
2024-03-06 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3350224B1
(en)
|
2015-09-20 |
2024-06-19 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
|
|
EP3660044A1
(en)
|
2015-10-09 |
2020-06-03 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
JP6991978B2
(ja)
|
2016-01-27 |
2022-02-03 |
メディミューン，エルエルシー |
定められるグリコシル化パターンを有する抗体を調製するための方法
|
|
WO2017136558A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
|
TW201808978A
(zh)
|
2016-03-08 |
2018-03-16 |
中央研究院 |
N-聚醣及其陣列之模組化合成方法
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
JP6735355B2
(ja)
|
2016-04-15 |
2020-08-05 |
バイオアトラ、エルエルシー |
抗Ａｘｌ抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
TW202434312A
(zh)
|
2016-05-13 |
2024-09-01 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
|
WO2018045325A1
(en)
|
2016-09-02 |
2018-03-08 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
KR102221364B1
(ko)
|
2016-11-21 |
2021-03-04 |
쿠레아브 게엠베하 |
항-gp73 항체 및 면역접합체
|
|
US11236171B2
(en)
|
2016-12-21 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
CN117946283A
(zh)
|
2017-01-09 |
2024-04-30 |
莱蒂恩技术公司 |
用于用抗间皮素免疫治疗癌症的组合物和方法
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
JP7137896B2
(ja)
|
2017-03-24 |
2022-09-15 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
CA3066953A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Human monoclonal antibodies specific for cd33 and methods of their use
|
|
CA3071624A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
|
ES2960419T3
(es)
|
2017-09-15 |
2024-03-04 |
Lentigen Tech Inc |
Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
|
|
AU2018337671B2
(en)
|
2017-09-19 |
2021-03-04 |
Paul Scherrer Institut |
Transglutaminase conjugation method and linker
|
|
EP3697426B1
(en)
|
2017-10-16 |
2023-07-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd22 immunotherapy
|
|
AU2018354189A1
(en)
|
2017-10-24 |
2020-04-23 |
Crispr Therapeutics Ag |
Compositions and methods for the depletion of CD117+ cells
|
|
AU2018360031B2
(en)
|
2017-11-03 |
2025-08-21 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-ROR1 immunotherapy
|
|
KR20200094181A
(ko)
|
2017-11-29 |
2020-08-06 |
마젠타 테라퓨틱스 인코포레이티드 |
Cd5+ 세포를 고갈시키기 위한 조성물 및 방법
|
|
WO2019126464A2
(en)
|
2017-12-20 |
2019-06-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating hiv/aids with immunotherapy
|
|
WO2020014482A1
(en)
|
2018-07-12 |
2020-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
|
EP3826625A4
(en)
|
2018-07-23 |
2022-08-24 |
Magenta Therapeutics, Inc. |
USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY
|
|
CN112585163B
(zh)
|
2018-08-08 |
2025-03-25 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
|
|
US10844128B2
(en)
|
2018-09-20 |
2020-11-24 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
CN118581122A
(zh)
|
2018-09-26 |
2024-09-03 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
|
WO2020113108A1
(en)
|
2018-11-30 |
2020-06-04 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
|
AU2020206308A1
(en)
|
2019-01-08 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
US12122843B2
(en)
|
2019-01-22 |
2024-10-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
AU2020232789A1
(en)
|
2019-03-06 |
2021-10-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
|
KR20220144753A
(ko)
|
2019-03-19 |
2022-10-27 |
폴 슈레 앙스띠뛰 |
글리신 기반 링커를 사용한 트랜스글루타미나제 컨쥬게이션 방법
|
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
CA3140102A1
(en)
|
2019-05-30 |
2020-12-03 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
|
EA202290208A1
(ru)
|
2019-07-02 |
2022-03-25 |
Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз |
МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ
|
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
|
JP7413519B2
(ja)
|
2019-10-18 |
2024-01-15 |
ジェネンテック， インコーポレイテッド |
びまん性大細胞型ｂ細胞リンパ腫を処置するための抗ｃｄ７９ｂ免疫抱合体の使用方法
|
|
CN119899265A
(zh)
|
2019-10-22 |
2025-04-29 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
|
|
JP7679380B2
(ja)
|
2019-12-12 |
2025-05-19 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Ｃｄ２７６に特異的な抗体－薬物コンジュゲートおよびその使用
|
|
EP4139359A1
(en)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
JP2023532448A
(ja)
|
2020-06-22 |
2023-07-28 |
レンティジェン・テクノロジー・インコーポレイテッド |
Ｔｓｌｐｒ－ｃｄ１９またはｔｓｌｐｒ－ｃｄ２２免疫療法によりがんを処置するための組成物および方法
|
|
JP2023542910A
(ja)
|
2020-09-18 |
2023-10-12 |
アラリス バイオテック アーゲー |
アミノ酸に基づくリンカーを使用したトランスグルタミナーゼコンジュゲーション方法
|
|
CA3196218A1
(en)
|
2020-10-25 |
2022-04-28 |
Philipp SPYCHER |
Means and methods for producing antibody-linker conjugates
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
WO2022099026A1
(en)
|
2020-11-05 |
2022-05-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
US20240218055A1
(en)
|
2021-04-29 |
2024-07-04 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
AU2022273063A1
(en)
|
2021-05-12 |
2023-11-23 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
BR112023024804A2
(pt)
|
2021-05-28 |
2024-02-15 |
Glaxosmithkline Ip Dev Ltd |
Terapias de combinação para tratar câncer
|
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CN118159294A
(zh)
|
2021-10-05 |
2024-06-07 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于治疗癌症的联合疗法
|
|
JP2024539989A
(ja)
|
2021-10-25 |
2024-10-31 |
アラリス バイオテック アーゲー |
抗体－リンカーコンジュゲートを生成する方法
|
|
CA3243937A1
(en)
|
2022-02-22 |
2023-08-31 |
Araris Biotech Ag |
PEPTIDE LINKS COMPRISING TWO OR MORE PAYLOADS
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
CA3263188A1
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric Antigen Receptor Therapies for the Treatment of Solid Tumors
|
|
WO2024044743A1
(en)
|
2022-08-26 |
2024-02-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
|
|
WO2024218345A1
(en)
|
2023-04-21 |
2024-10-24 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
|
|
CN121285742A
(zh)
|
2023-06-08 |
2026-01-06 |
基因泰克公司 |
用于淋巴瘤的诊断和治疗方法的巨噬细胞特征
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025082990A1
(en)
|
2023-10-15 |
2025-04-24 |
Araris Biotech Ag |
Antibody-drug conjugates using two different types of topoisomerase i inhibitors
|
|
WO2025171238A1
(en)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2026006682A1
(en)
|
2024-06-27 |
2026-01-02 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating cancer with il7fc armored car-t cells
|